1. Web site: www.bioscicon.com
BioSciCon, Inc.
Business Opportunity
2006
Web site:
January 15, 2019

2. BioSciCon, Inc.
BioSciCon has developed and manufactures patented biomarker-based MarkPap® technology products intended for early detection of cervical cancer. This technology is more accurate, less costly and less invasive than current Pap test technologies.
January 15, 2019

3. Cervical Cancer is preventable
Cervical cancer is second to the breast cancer cause of women deaths from malignant diseases world-wide. Currently, there are 500,000 new cases of cervical cancer each year, and about 250,000 die from this preventable disease in 21st Century. However, cervical cancer is preventable IF detected on time. Best prevention is regular cervical cancer screening. Cytological screening (Pap test) remains the best cervical cancer prevention.
January 15, 2019

4. WORLD Problem At risk: 1.7 B Protected with Pap 110 M or 6.5%
Developing countries: 20 M Pap tests or 1.2%
Other technologies
Screen & treat
VIA
HPV
Vaccination
January 15, 2019

5. The Problem Existing Pap Test Technology:
Costly: Increasing insurance costs in US and prohibitively expensive in developing countries
Infrastructure: required, with qualified professionals (cytotechnologists/pathologists)
Insufficient Reliability: (>15% false negatives)
Slow: Takes weeks to obtain normal results
Requires visiting a doctor and it is invasive, which leads to fewer women being tested
January 15, 2019

6. The Solution MarkPap® Test is the solution:
Less costly: Priced >25% less than Pap test
MarkPap Self and MarkPap Digital make the infrastructure affordable for developing countries
More reliable: <5% false negatives
Less Invasive: MarkPap Self, leading to increased use by all women
Timely: Results within hours (MarkPap Digital)
Better controlled: QC/QA with control slides and less liability for the laboratory
January 15, 2019

7. MarkPap® Technology CAP-PAP Test (US patent, 2000) CAP-PAP Kit
(US patent pending)
International
(PCT, 2004)
Trademark MarkPap®
Know-how
Chemical sensitive
biomarker flags
abnormal cells for
early detection.
January 15, 2019

8. MarkPap Images Abnormal specimen, ASC-H.
Three small abnormal (red) cells
among several normal cells.
Screening magnification (left).
Diagnostic magnifications (right).
Abnormal cells cannot be missed.
January 15, 2019

9. MarkPap® Products (first line of products)
MarkPap® Research Kit: Assembly of reagents, instructions and controls.
Kit Accessories: Cytopreservative solution, Control slides.
MarkPap® Test: service, assay.
Available for research only in the US (before FDA approval). International sale under local regulations.
January 15, 2019

10. MarkPap Research Kit
January 15, 2019

11. MarkPap Accessories
January 15, 2019

12. Products in Development
MarkPap® Self
MarkPap® Digital
MarkPap® Self Digital
MarkPap® Cell Bank
January 15, 2019

13. MarkPap Self
January 15, 2019

14. MarkPap Self
MarkPap Self is an option for women to take the sample in the privacy of their home and to send it in the laboratory. MarkPap Self is aimed for women who live in remote parts and do not have access to doctors offices, for those who (because of different cultural and religious tradition) cannot go to gynecologist, or women who are simply not comfortable with pelvic exam and prefer to take the sample at home. MarkPap Self will dramatically increase the number of women who will get preventive testing.
January 15, 2019

15. MarkPap Digital
January 15, 2019

16. MarkPap Digital
MarkPap Digital provides a possibility to process the sample in a small laboratory/doctor office, capture the “red” biomarker positive (abnormal) cells with a digital camera and transmit images via Internet into laboratories with qualified reviewers for evaluation. The result may be available within hours. The cost of the image acquisition system consisting of a microscope, digital camera and software is below $5,000.
January 15, 2019

17. MarkPap Self Digital
In practice, MarkPap Self and MarkPap Digital allow women to take the sample at home and to mail it to the nearby laboratory. In this laboratory a low-trained technician or nurse can stain the slide using easy-to-use MarkPap Kit. The same person examines the slide under the microscope and searches for “red” cells. The images of those cells are captured with a digital camera and transmitted for evaluation. The result may be sent back electronically within hours. This is how MarkPap technology can provide cytological mass cervical screening worldwide and save women’s lives.
January 15, 2019

18. Overall Competitive Advantages
Novel biomarker of abnormality
Simple and immediately applicable
Better accuracy for lower cost
Better productivity for less liability
Prospect for self-sampling and telecytopathology for mass cervical cancer screening worldwide
Huge societal benefit saving women’s lives with enormous market and incredible potential for profit
January 15, 2019

19. BioSciCon, Inc.
BioSciCon is a small business, women owned, start-up S-corporation, which has completed the R&D phase for the first line products, and has entered a new development phase for the next line of products. The company is now searching for commercial funding to bring products to market.
More about BioSciCon at
January 15, 2019

20. Management team Nenad Markovic, MD. PhD, President
Olivera Markovic, M.D. PhD, Founding Director
Executive Secretary
Clinical and Laboratory Sites Managers
20 Ob/Gyn, 4 pathologists and GPs in U.S. (MD, DC, CA, NY, FL) and abroad
Mr. Peter Ricca, Ricca Chemical Company, Manufacturer
MarkPap LLC, the business arm of BioSciCon (see next)
Organizational structure presented at
January 15, 2019

21. MarkPap LLC
BioSciCon has recently incorporated a new business entity, the MarkPap LLC. The LLC has initiated an executive search from the pool of business professionals who already expressed strong interest to become LLC Managing Partners.
January 15, 2019

22. Web site: www.bioscicon.com E-mail: info@bioscicon.com
BioSciCon, Inc.
14905 Forest Landing Circle
Rockville, MD 20850
Tel:
Fax:
Web site:
January 15, 2019